MARKET

GALT

GALT

Galectin Therapeutics Inc
NASDAQ
4.670
+0.610
+15.02%
Opening 12:29 07/13 EDT
OPEN
4.060
PREV CLOSE
4.060
HIGH
4.820
LOW
4.010
VOLUME
761.72K
TURNOVER
--
52 WEEK HIGH
7.13
52 WEEK LOW
2.025
MARKET CAP
307.55M
P/E (TTM)
-11.3764
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GALT last week (0706-0710)?
Weekly Report · 18h ago
Weekly Report: what happened at GALT last week (0629-0703)?
Weekly Report · 07/06 09:10
Galectin Therapeutics CMO Jamil Khurram disposes of common shares worth $262,943
PUBT · 06/30 23:23
Top 3 Health Care Stocks That May Keep You Up At Night In June
Benzinga · 06/30 12:55
Weekly Report: what happened at GALT last week (0622-0626)?
Weekly Report · 06/29 09:09
Galectin Therapeutics CMO Jamil Khurram disposes of 7,557 common shares worth $23,728.98
PUBT · 06/25 20:07
Top Biotech Gainers: PLSM Inks Virtual Maternity Care Deal, ICCM Turns Heads, SLN Hits New High
NASDAQ · 06/25 03:47
Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside
Seeking Alpha · 06/24 18:02
More
About GALT
Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.

Webull offers Galectin Therapeutics Inc stock information, including NASDAQ: GALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GALT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GALT stock methods without spending real money on the virtual paper trading platform.